For some time, researchers have known that people with diabetes have a greater risk of developing Alzheimer’s disease and other forms of dementia than those without diabetes, but the exact cause of this link has not been known. Now, a new study by researchers in Cologne, Germany, and at Joslin Diabetes Center in Boston, to be published this week online in the Proceedings of the National Academy of Sciences, suggests that insulin resistance in brain cells can affect how they function, causing some of the biochemical changes typically seen in Alzheimer’s disease.
Insulin resistance is a major contributor to type 2 diabetes, obesity and the metabolic syndrome, which affect nearly one-quarter of the American population. In these insulin resistant states, tissues of the body such as muscle, liver, and fat fail to respond normally to the insulin produced by the pancreas, leading to a wide range of metabolic abnormalities. In patients with diabetes, this includes elevated blood sugar levels which, if uncontrolled, can lead to such vascular complications as blindness, limb amputations, kidney disease, heart disease, stroke and nerve damage.
Through research at Joslin Diabetes Center and elsewhere, scientists only recently have come to realize that insulin receptors are present on all tissues of the body, including the brain, and may affect the function of these tissues. Furthermore, various research findings have suggested that disruption of the insulin signaling system may occur in such disorders as Alzheimer’s disease and Parkinson’s disease. In fact, at least one large European study found people with diabetes to be at least twice as likely to develop Alzheimer’s disease as someone without the disease. The risk was even higher among those people with diabetes taking insulin, informs &to=http://www.scotsman.com' target=_blank>Scotsman
To study the effects of insulin resistance in the brain, Jens C. Bruning, M.D., formerly of Joslin Diabetes Center and now of the University of Cologne, Germany, and his colleagues and C. Ronald Kahn, M.D., of Joslin Diabetes Center in Boston, used genetically altered mice called Neuronal Insulin Receptor Knockout (NIRKO) mice, which are missing insulin receptors in their neurons (brain cells). Compared with normal mice, NIRKO mice had markedly reduced activity of insulin signaling proteins in the brain. This was found to lead to overactivity of an enzyme called GSK3 beta, which in turn, led to excessive phosphorylation (or hyperphosphorylation) of a protein called tau.
Hyperphosphorylation of tau is a hallmark of brain lesions seen in Alzheimer's disease and has been suggested to be an early marker of this disease. On the other hand, the NIRKO mice showed no changes in the proliferation or survival of neurons, memory, or basal brain glucose metabolism, suggesting that insulin resistance may interact with other risk factors to promote full-blown Alzheimer's disease.
After it turned out that Deputy Prime Minister Andrei Belousov included the Fonbet betting company in the list of backbone enterprises that can count on state support, everyone started talking about these bookmakers.